These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 11013012)
81. C5aR ligand peptide 3D QSAR study performed with an applied linear conformation. Anderson CY; Kellogg GE; Freer RJ J Pept Res; 1997 Jun; 49(6):476-83. PubMed ID: 9266474 [TBL] [Abstract][Full Text] [Related]
82. A neuronal C5a receptor and an associated apoptotic signal transduction pathway. Farkas I; Baranyi L; Takahashi M; Fukuda A; Liposits Z; Yamamoto T; Okada H J Physiol; 1998 Mar; 507 ( Pt 3)(Pt 3):679-87. PubMed ID: 9508829 [TBL] [Abstract][Full Text] [Related]
83. Characterization of C5aR expression on murine myeloid and lymphoid cells by the use of a novel monoclonal antibody. Soruri A; Kim S; Kiafard Z; Zwirner J Immunol Lett; 2003 Jul; 88(1):47-52. PubMed ID: 12853161 [TBL] [Abstract][Full Text] [Related]
84. Measurement of complement activation in rabbit plasma or serum using monoclonal antibodies against C5a. Bergh K; Iversen OJ Scand J Immunol; 1989 Mar; 29(3):333-41. PubMed ID: 2470136 [TBL] [Abstract][Full Text] [Related]
85. Evidence that the extracellular N-terminal domain of C5aR contains amino-acid residues crucial for C5a binding. Mery L; Boulay F Eur J Haematol; 1993 Nov; 51(5):282-7. PubMed ID: 8282089 [TBL] [Abstract][Full Text] [Related]
86. C5a mutants are potent antagonists of the C5a receptor (CD88) and of C5L2: position 69 is the locus that determines agonism or antagonism. Otto M; Hawlisch H; Monk PN; Müller M; Klos A; Karp CL; Köhl J J Biol Chem; 2004 Jan; 279(1):142-51. PubMed ID: 14570896 [TBL] [Abstract][Full Text] [Related]
87. Molecular characterization of the gerbil C5a receptor and identification of a transmembrane domain V amino acid that is crucial for small molecule antagonist interaction. Waters SM; Brodbeck RM; Steflik J; Yu J; Baltazar C; Peck AE; Severance D; Zhang LY; Currie K; Chenard BL; Hutchison AJ; Maynard G; Krause JE J Biol Chem; 2005 Dec; 280(49):40617-23. PubMed ID: 16230349 [TBL] [Abstract][Full Text] [Related]
88. PMX-53 as a dual CD88 antagonist and an agonist for Mas-related gene 2 (MrgX2) in human mast cells. Subramanian H; Kashem SW; Collington SJ; Qu H; Lambris JD; Ali H Mol Pharmacol; 2011 Jun; 79(6):1005-13. PubMed ID: 21441599 [TBL] [Abstract][Full Text] [Related]
89. Species dependence for binding of small molecule agonist and antagonists to the C5a receptor on polymorphonuclear leukocytes. Woodruff TM; Strachan AJ; Sanderson SD; Monk PN; Wong AK; Fairlie DP; Taylor SM Inflammation; 2001 Jun; 25(3):171-7. PubMed ID: 11403208 [TBL] [Abstract][Full Text] [Related]
90. Experimental diffuse axonal injury induces enhanced neuronal C5a receptor mRNA expression in rats. Stahel PF; Kossmann T; Morganti-Kossmann MC; Hans VH; Barnum SR Brain Res Mol Brain Res; 1997 Oct; 50(1-2):205-12. PubMed ID: 9406936 [TBL] [Abstract][Full Text] [Related]
91. Molecular cloning and characterization of the human anaphylatoxin C3a receptor. Ames RS; Li Y; Sarau HM; Nuthulaganti P; Foley JJ; Ellis C; Zeng Z; Su K; Jurewicz AJ; Hertzberg RP; Bergsma DJ; Kumar C J Biol Chem; 1996 Aug; 271(34):20231-4. PubMed ID: 8702752 [TBL] [Abstract][Full Text] [Related]
93. Structure of the tyrosine-sulfated C5a receptor N terminus in complex with chemotaxis inhibitory protein of Staphylococcus aureus. Ippel JH; de Haas CJ; Bunschoten A; van Strijp JA; Kruijtzer JA; Liskamp RM; Kemmink J J Biol Chem; 2009 May; 284(18):12363-72. PubMed ID: 19251703 [TBL] [Abstract][Full Text] [Related]
94. Probing the "message:address" sites for chemoattractant binding to the C5a receptor. Mutagenesis of hydrophilic and proline residues within the transmembrane segments. Kolakowski LF; Lu B; Gerard C; Gerard NP J Biol Chem; 1995 Jul; 270(30):18077-82. PubMed ID: 7629117 [TBL] [Abstract][Full Text] [Related]